Molecular Imaging in Risk Stratification and Adjuvant Therapy Main Discussion Topics: Potential role in identifying patients appropriate for adjuvant pembrolizumab after nephrectomy Possible utility ...

Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic ...

Improving Clinical Trial Diversity Key Themes: A multistakeholder approach is required (patients, communities, clinicians, payers, industry). Community outreach initiatives are essential for building ...

Diagnostic Performance of the ZIRCON Trial Main Discussion Topics: A 93% to 95% positive predictive value for clear cell renal cell carcinoma (ccRCC) A 75% negative predictive value Important ...

Recent data show that the use of minimally invasive surgical therapies (MISTs) for the management of benign prostatic hyperplasia (BPH) is increasing among men aged 50 to 65. 1 Overall, MIST ...

Urologists from Cleveland Clinic recently collaborated across borders to perform the world’s first remotely conducted robot–assisted high-intensity focused ultrasound (HIFU) focal therapy procedure ...

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

The disparity in DO and MD cohort sizes is linked to organizational changes that have affected DO applicant participation in the urology match. Before the transition to single accreditation of US ...

There has been an explosion of treatment options in non–muscle invasive bladder cancer (NMIBC) in recent years, with even more coming down the pike. Many of these agents have demonstrated encouraging ...

Computational Histology Artificial Intelligence (CHAI) biomarkers demonstrated the ability to prognosticate outcomes for patients with high-grade (HG) Ta non–muscle-invasive bladder cancer (NMIBC), ...

Currently, several FDA-approved agents treat BCG-unresponsive carcinoma in situ (CIS), with or without papillary disease. Pembrolizumab, a single-agent checkpoint inhibitor, has a complete response ...

Key Takeaways 64Cu-SAR-Bombesin targets GRPR, showing efficacy in detecting prostate cancer recurrence in PSMA-negative patients with negative SOC imaging results. The SABRE trial enrolled 53 patients ...